Video: Jeremy Levin On Pharma To Biotech CEO Migration
This article was originally published in Scrip
Teva's former CEO Jeremy Levin is now heading up a start-up focused on neuroscience therapies. At BioPharm America, he discussed the trend of executives moving from large pharma to smaller companies, as well as the business strategy for his new firm.
You may also be interested in...
The JVs will develop and commercialize therapeutics for multiple cancer types and autoimmune disorders in China. Novocure partners its Tumor Treating Fields technology with Zai Lab, while Fate and ONO will collaborate on off-the-shelf CAR-T therapies.
Stakeholders are eager for details on the Takeda/Shire merger and on what Trump said to Pfizer CEO Ian Read to cause the recent about-face on price increases. Other key topics will be status updates on Teva's Copaxone franchise and on Novo Nordisk's oral semaglutide.
Yescarta continued its growth trajectory, the HIV franchise showed solid sales growth and the hepatitis C franchise stayed steady – plus Gilead could jump to the head of the line in NASH.